Company: CMND
Filing Date: 2025-11-26
Form Type: F-1
Source: 0001213900-25-115501
Chunk: 12

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: F-1
Chunk 12
---
i) 958,222 common shares, and (ii) pre-funded warrants
to purchase up to 2,984,146 common shares, in a registered direct offering, or the First November 2025 Offering, at a purchase price of
$0.20 per common share and $0.1999 per pre-funded warrant. The pre-funded warrants are immediately exercisable at an exercise price of
$0.0001 per common share, subject to adjustment as set forth therein, and will not expire until exercised in full. The November 2025 Offering
closed November 13, 2025. The aggregate gross proceeds to the Company were approximately $0.788 million.

On November 17, 2025, we entered into a securities
purchase agreement with investors for the purchase and sale of (i) 3,991,768 common shares, and (ii) pre-funded warrants to purchase up
to 1,518,000 common shares, in a registered direct offering, or the Second November 2025 Offering, at a purchase price of $0.25 per common
share and $0.2499 per pre-funded warrant. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common
share, subject to adjustment as set forth therein, and will not expire until exercised in full. The Second November 2025 Offering closed
November 17, 2025. The aggregate gross proceeds to the Company were approximately $1.377 million.

On November 19, 2025, we entered
into a securities purchase agreement with investors for the purchase and sale of 10,925,000 common shares in a registered direct offering,
or the Third November 2025 Offering, at a purchase price of $0.20 per common share. The Third November 2025 Offering closed November 20,
2025. The aggregate gross proceeds to the Company were approximately $2.185 million.

Warrant Exercises

As of November 14, 2025, investors
from our financings in April 2023 and January 2024 exercised an aggregate of warrants to purchase 2,894,769 common shares, including warrants
to purchase 1,881,250 common shares on a cashless basis. As a result, we issued an aggregate of 2,090,987 common shares and received aggregate
gross proceeds of approximately $183,000 from such exercises.

Convertible Notes Securities Purchase Agreement

On September 17, 2025